Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
about
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
description
im Oktober 2018 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2018
@uk
name
Safety, tolerability and effic ...... cebo-controlled phase 2a study
@en
Safety, tolerability and effic ...... cebo-controlled phase 2a study
@nl
type
label
Safety, tolerability and effic ...... cebo-controlled phase 2a study
@en
Safety, tolerability and effic ...... cebo-controlled phase 2a study
@nl
prefLabel
Safety, tolerability and effic ...... cebo-controlled phase 2a study
@en
Safety, tolerability and effic ...... cebo-controlled phase 2a study
@nl
P2093
P2860
P1476
Safety, tolerability and effic ...... cebo-controlled phase 2a study
@en
P2093
Alida A Gouw
Alle Meije Wink
Caroline M van Baal
John Harrison
Merja Hallikainen
Niels D Prins
Paul Maruff
Suzanne Bruins
Thomas Duning
P2860
P2888
P356
10.1186/S13195-018-0431-6
P407
P577
2018-10-12T00:00:00Z
P6179
1107561346